Introduction
Apoptosis represents a physiological mechanism that eliminates damaged cells from an organism, thus controlling cell numbers and tissue size, and sustaining homeostasis. Suppression of apoptosis implicates deregulated cell proliferation and predisposition to cancer. The transmembrane death receptors of the tumour necrosis factor (TNF) receptor superfamily mediate the activation of the central forces of regulated cell death-the caspases-triggering cell dissolution (1, 2) .
The proapoptotic death receptor 4 (DR4, TNFRSF10A, TRAILR-1) has been characterized as the first DR to efficiently bind the TNF-related apoptosis-inducing ligand (TRAIL) (3) . DR4, located on chromosome 8p21-22, encodes 486 amino acids which form two extracellular cysteine-rich, ligand-binding pseudorepeats (50s and 90s loops), a single transmembrane helix and a cytoplasmic death domain which provokes apoptosis upon TRAIL binding (4) (5) (6) . Allelic losses of 8p21-22 (7-10) and a decreased expression of DR4 mRNA in breast cancer cell lines and tumours have been shown to facilitate the inhibition of tumour suppression, thus very likely contributing to malignant phenotypes (5, 11) . DR4 mutations have been described in different human cancers, such as lung, head and neck cancer, non-Hodgkin's lymphoma as well as in breast cancer and breast cancer cell lines (5, 12, 13) , which points to DR4 as an attractive candidate tumour suppressor gene. Several genotyping studies have addressed the association of DR4 Thr209Arg in different types of cancer, but the results have been controversial (12, 14, 15) . This is the first case-control study to investigate the effect of the DR4 variant Glu228Ala (683A4C), along with Thr209Arg (626C4G), on familial breast cancer risk, revealing an increased risk for carriers of the 626C-683C haplotype.
Materials and methods

Subjects
The breast cancer cases consisted of 521 unrelated German women (21-87 years of age; mean age 44.6) without BRCA1 and BRCA2 mutations. According to the German Consortium for Hereditary Breast and Ovarian Cancer they were classified into six categories based on family history: (i) families with two or more breast cancer cases including at least two cases with onset below the age of 50; (ii) families with at least one male breast cancer case; (iii) families with at least one breast cancer and one ovarian cancer case; (iv) families with at least two breast cancer cases comprising one case diagnosed before the age of 50; (v) families with at least two breast cancer cases diagnosed after the age of 50; and (vi) single cases of breast cancer diagnosed before the age of 35 (16) . They were registered during the years 1997-2004 through the Institute of Human Genetics (Heidelberg, Germany), the Department of Gynaecology and Obstetrics (Cologne, Germany) and the Department of Medical Genetics (Munich, Germany). The control series included 1100 healthy and unrelated female blood donors (18-68 years of age, mean age 41.0) having the ethnic background of the breast cancer patients, registered by the Institute of Transfusion Medicine and Immunology (Mannheim, Germany). The study was approved by the Ethics Committee of the University of Heidelberg (Heidelberg, Germany).
Single nucleotide polymorphism selection
In order to validate annotated DR4 single nucleotide polymorphisms (SNPs; dbSNP database, http://www.ncbi.nlm.nih.gov/) and to select positive controls for subsequent TaqMan allelic discrimination assays, genomic DNA of 20 randomly chosen German breast cancer patients were used for sequencing. This analysis comprised three non-synonymous coding DR4 SNPs (Thr33Ile, Thr209Arg and Glu228Ala; Table I), Thr209Arg and Glu228Ala being confirmed. Since the DR4 variant His141Arg has been shown to cosegregate with Thr209Arg (12), we abandoned further investigation. 
Genotyping
Both DR4 Thr209Arg and Glu228Ala were genotyped using TaqMan allelic discrimination assays. The design of TaqMan probes as well as primers was done with the Applied Biosystems Assay-by-Design service (Table I) . As it has been shown that even rare polymorphisms in the vicinity of the SNP to be analysed might falsify TaqMan results, the SNP assays were validated by sequencing 44% of samples, attaining a concordance rate of 100% (17) . Genotype distributions were consistent with the Hardy-Weinberg equilibrium. PCR amplification and sequencing were performed as previously described (18) .
Statistical analysis
Calculations of Hardy-Weinberg equilibrium, genotype-specific odds ratios (ORs) and 95% confidence intervals (95% CIs) were carried out using a tool offered by the Institute of Human Genetics, Technical University Munich, Munich, Germany (http://ihg.gsf.de/cgi-bin/hw/hwa1.pl). Ageadjusted ORs and corresponding 95% CIs were computed by means of unconditional logistic regression using the Statistical Analysis System software (Version 8.2.; SAS Institute Inc., Cary, NC). P-values were calculated using two-sided x 2 -tests. Haplotypes were determined using the PHASE 2 software created by Matthew Stephens (http://archimedes.well.ox.ac.uk/pise/PHASE. html) (19) .
Results and discussion
Members of the TNF receptor family are thought to play a pivotal role in carcinogenesis by regulating apoptotic events. Assuming that genetic variations in DR4 might affect individual breast cancer risk, we investigated the prevalence of annotated DR4 polymorphisms in a set of 20 DNA samples from breast cancer patients and confirmed Thr209Arg and Glu228Ala (Table I) . Both SNPs reside next to the DR4 ligand-binding ectodomain and may affect TRAIL binding, and-as a result-apoptotic signalling (12) . To evaluate their influence on breast cancer risk, a case-control study was performed using 521 German BRCA1 and BRCA2 mutation negative breast cancer cases and 1100 control samples. While several reports have controversially discussed the impact of the Thr209Arg variant on breast, bladder, lung, head and neck cancer risk (12, 14, 15) , this is the first study to investigate the role of DR4 Glu228Ala and DR4 haplotypes on cancer predisposition. Thr209Arg showed no significance with regard to breast cancer risk (OR ¼ 0.84, 95% CI ¼ 0.65-1.08, P ¼ 0.18; Table II ). These results are in agreement with the previously published data using subjects from Sheffield, UK (15) . Similarly, Glu228Ala did not show any association with breast cancer risk (OR ¼ 0.89, 95% CI ¼ 0.72-1.12, P ¼ 0.30, Table II ). Adjustment for age did not change the ORs of the respective SNPs (Thr209Arg: OR ¼ 0.83, 95% CI ¼ 0.64-1.07, P ¼ 0.16; Glu228Ala: OR ¼ 0.87, 95% CI ¼ 0.69-1.08, P ¼ 0.20). Neither variants exhibited a significant association with breast cancer risk after stratification according to age at diagnosis (550; !50). Combining DR4 Thr209Arg and Glu228Ala for the haplotype analysis resulted in four distinct haplotypes (Table III) . Investigation of the respective haplotypes for linkage to breast cancer showed no association of 626C-683A and 626G-683A with breast cancer risk (Table III) . The common haplotype 626G-683C showed a decreased OR with a borderline significance (OR ¼ 0.86, 95% CI ¼ 0.71-1.04, P ¼ 0.11, Table III ; age-adjusted OR ¼ 0.84, 95% CI ¼ 0.70-1.02, P ¼ 0.08). However, analysis of the rare haplotype 626C-683C revealed a significant difference in frequency when comparing breast cancer cases with control samples, resulting in an increased risk of breast cancer with an OR of 3.52 (95% CI ¼ 1.45-8.56, P ¼ 0.003, Table III ; age-adjusted OR ¼ 3.20, 95% CI ¼ 1.31-7.83, P ¼ 0.01). The observed association indicates that the combination of 626C and 683C might be functionally relevant by altering TRAIL binding or that 626C-683C might be in linkage disequilibrium with a functional variant residing in DR4 or in neighbouring genes. Since the haplotype 626C-683C is very rare, it represents a moderate amount of risk regarding familial breast cancer in general. Although the effect of 626-683C is high (OR ¼ 3.52), it is based on small numbers (Table III) . As a result, additional studies would be valuable to specify our risk assessment.
In summary, this study showed a significant association between the DR4 haplotype 626C-683C and increased risk of developing breast cancer in a German population. ORs, 95% CIs and corresponding P-values were determined by comparing each haplotype with the remaining haplotypes. P-values were calculated using two-sided x 2 -test.
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